The Neurotachykinin NK1 Receptor – A Novel Target for Diagnostics and Therapy

ISSN: 2211-5544 (Online)
ISSN: 2211-5552 (Print)

Volume 4, 2 Issues, 2015

Download PDF Flyer

Current Molecular Imaging (Discontinued)

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Abass Alavi
Department of Radiology/Nuclear Medicine
Hospital of the University of Pennsylvania
Philadelphia, PA 19104

View Full Editorial Board

Purchase Articles Order Reprints

The Neurotachykinin NK1 Receptor – A Novel Target for Diagnostics and Therapy

Current Molecular Imaging (Discontinued), 2(2): 130-147.

Author(s): Susanne Nikolaus, Maria Angelica de Souza Silva, Hubertus Hautzel and Hans-Wilhelm Muller.

Affiliation: Clinic of Nuclear Medicine, University Hospital Dusseldorf, Moorenstr. 5, D-40225 Dusseldorf, Germany.


Despite the knowledge, which has been accumulated on the central and peripheral actions of the neurokinin (NK) substance P (SP) over the last 80 years, it is only beginning to receive the attention of nuclear medicine physicians and scientists. Recently, two foci of interest have emerged: firstly, the performance of in vivo imaging studies of cerebral NK1 receptor binding with non-peptidergic NK1 receptor radioligands, and, secondly, radionuclide therapy with radiolabelled SP analogues targeting NK1 receptor binding sites. The present paper gives an overview on the utilization of nonpeptidergic and peptidergic NK1 receptor radioligands in diagnostics and therapy.


Aprepitant, anxiety disorder, chronic pain, depression, epilepsy, glioma, NK1 receptor, substance P.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 2
Issue Number: 2
First Page: 130
Last Page: 147
Page Count: 18
DOI: 10.2174/2211555211302020004
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science